RESEARCH ON FORMULATION DEVELOPMENT AND EVALUATION OF MOUTH DISSOLVING BILASTINE TABLETS
Pallavi Saini*, Arindam Chatterjee, Aditya Mishra, Rakesh Kumar Gupta, Deeksha Sharma
Jaipur college of Pharmacy, Jaipur Rajasthan, India
*sainipallavi838@gmail.com
ABSTRACT
AIM: To formulation development and evaluation of Mouth Dissolving Tablets of Bilastine H1 Second generation anti Histamine drug by using superdisintegrating agents. Thus mouth dissolving tablets are beneficial to patients who find it difficult to swallow tablets and moreover some of the drugs which are soluble in saliva are absorbed from the mouth, pharynx and oesophagus there thereby avoiding first pass metabolism which enhances bioavailability of the drug.
OBJECTIVE: The objective of the work is to prevent inherent drawbacks associated with conventional tablets such as risk of choking, bitter taste and difficult in swallowing by formulating mouth dissolving tablets of Bilastine there by providing faster disintegration and rapid release, bypassing first pass effect, improved patient compliance and therapeutic effectiveness.
RESULT AND SUMMERY: From the overall results, the study concluded that orally disintegrating tablets of Bilastine could be successfully formulated by direct compression method using crospovidone as superdisintegrant, which could be a promising formulation to effectively treat the symptoms of allergic disorders (e.g. rhinoconjunctivitis and urticaria) in adults and adolescents and, more recently, in children, thereby preventing inherent drawbacks associated with conventional tablets such as risk of choking, bitter taste and difficult in swallowing, also providing faster disintegration, rapid release, bypassing first pass effect, improve patient compliance and therapeutic effectiveness. From all the above observation it was concluded that the formulation F-VII containing crospovidone as superdisintegrant along with mannitol and microcrystalline cellulose as diluent was found to be better one compared to the other formulations and satisfied the criteria for orally disintegrating tablets.
KEYWORDS: Mouth dissolving tablet, improved patient compliance Bilastine, rhinoconjunctivitis and urticaria
